COVIDSeq Test (RUO Version)

This high-throughput next-generation sequencing (NGS) assay detects RNA from the SARS-CoV-2 virus. Read More...


Key Features and Benefits
  • Accuracy: Detects 98 targets on SARS-CoV-2 for highly accurate detection
  • Quality Control: Internal control consists of 11 human mRNA targets in every reaction
  • Flexibility: Available on NovaSeq 6000 S4 and SP flow cells and on NextSeq 500/550/550Dx (in RUO mode) HO flow cell

Product Highlights

The Illumina COVIDSeq Test (RUO version), an amplicon-based NGS assay, includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus for clinical research applications.

Rapid, Scalable SARS-CoV-2 Detection

The Illumina COVIDSeq Test (RUO version) can be scaled up or down to accommodate different numbers of samples. 1536 to 3072 results can be processed in 12 hours on NovaSeq 6000 system using two SP or S4 reagent kits, respectively or 384 results in 12 hours using NextSeq 500/550/550Dx (in RUO mode) HO reagent kit.

Workflow and Components

The workflow includes steps for viral RNA extraction, RNA-to-cDNA conversion, PCR, library preparation, sequencing, analysis, and report generation. Key components include the high-throughput NovaSeq 6000 System or the NextSeq 500/550/550Dx (in RUO mode) Systems, coupled with the Illumina COVIDSeq Test (RUO version) and the DRAGEN COVIDSeq Test Pipeline (RUO version) or DRAGEN COVIDSeq Test App (RUO version) in BaseSpace Sequence Hub for rapid analysis.

Design and Quality Control

The Illumina COVIDSeq Test (RUO version) leverages a modified version of the validated, publicly available ARTIC multiplex PCR protocol, with 98 amplicons designed to amplify SARS-CoV-2 virus-specific sequences, combined with proven Illumina sequencing technology. As a quality feature, an internal control consisting of 11 human mRNA targets is included in every sample.

Frequently Purchased Together


High-Level Workflow